Membrane microvesicle shedding is an active process and occurs in viable cells with no signs of apoptosis or necrosis. We report here that microvesicles shed by oligodendroglioma cells contain an 'aggrecanase' activity, cleaving aggrecan at sites previously identified as targets for adamalysin metalloproteinases with disintegrin and thrombospondin domains (ADAMTSs). Degradation was inhibited by EDTA, the metalloproteinase inhibitor GM6001 and by tissue inhibitor of metalloproteinases (TIMP)-3, but not by TIMP-1 or TIMP-2. This inhibitor profile indicates that the shed microvesicles contain aggrecanolytic ADAMTS(s) or related TIMP-3-sensitive metalloproteinase(s). The oligodendroglioma cells were shown to express the three most active aggrecanases, namely Adamts1, Adamts4 and Adamts5, suggesting that one or more of these enzymes may be responsible for the microvesicle activity. Microvesicles shed by rheumatoid synovial fibroblasts similarly degraded aggrecan in a TIMP-3-sensitive manner. Our findings raise the novel possibility that microvesicles may assist oligodendroglioma and rheumatoid synovial fibroblasts to invade through aggrecan-rich extracellular matrices.
Introduction
An increasing number of cell types have been shown to shed microvesicles (MVs) under both physiological and pathological conditions. MVs have been demonstrated to contain a wide array of biological effector molecules, including proteins, lipids, DNA, microRNA and mRNA, and since MVs can interact with other cells, they can serve as a means of cell-to-cell communication (Mathivanan et al., 2010) . MVs can interact with other cells either through direct membrane fusion, or by utilising adhesion molecules such as L1 (Gutwein et al., 2005) and CD44 (Stoeck et al., 2006) , or signalling molecules such as integrins (Dolo et al., 1998; Taraboletti et al., 2002 ) located on the MV surface. MVs can initiate various biological events in target cells, ranging from apoptosis (D'Agostino et al., 2006; Lo Cicero et al., 2011) to cell survival and proliferation (Deregibus et al., 2007; Skog et al., 2008) . They have also been shown to mediate horizontal mRNA transfer (Deregibus et al., 2007; Skog et al., 2008) .
Fibroblasts (Lee et al., 1993) , reticulocytes (Johnstone et al., 1987) , endothelial cells (Taraboletti et al., 2002) , lymphocytes (Raposo et al., 1996) , dendritic cells (Zitvogel et al., 1998) and platelets (Heijnen et al., 1999) , as well as by numerous cancer cell types (Ginestra et al., 1997; Dolo et al., 1998) have been shown to shed MVs. The MV population can be subdivided into exosomes and shedding vesicles based on their size and origin. Exosomes are 40-100 nm in diameter and are derived from endosomal multivesicular bodies (Théry et al., 2002) , while shedding vesicles are 100-1000 nm in diameter and are generated by outward budding of the plasma membrane (Cocucci et al., 2009) . Cells commonly release both exosomes and shedding vesicles into the extracellular space, with this mixed population referred to as 'microvesicles' (MVs).
MVs shed by tumour cells contain tumour antigens and can thus contribute to immune system evasion (Andre et al., 2002) . Tumour MVs may also contribute to tumour invasion, as they contain proteinases that degrade the ECM. For example, MVs have been demonstrated to contain cathepsin B (Giusti et al., 2008) , matrix metalloproteinase (MMP)-2 (Ginestra et al., 1997) , MMP-9 (Ginestra et al., 1997; Dolo et al., 1998) , MT1-MMP (Taraboletti et al., 2002) , and urokinase-type plasminogen activator (Ginestra et al., 1997) , as well as the adamalysins ADAM10 (Gutwein et al., 2005; Stoeck et al., 2006) and ADAM17 (Stoeck et al., 2006) .
We have previously shown that G26/24 oligodendroglioma cells shed MVs, which contain Fas ligand and tumour necrosis factor α-related apoptosis-inducing ligand and induce apoptosis in neurons and astrocytes (D'Agostino et al., 2006; Lo Cicero et al., 2011) . In addition to their effects on healthy cells within the brain, oligodendrogliomas remodel the brain extracellular matrix (ECM) and invade into surrounding tissues (Bellail et al., 2004) . Along with other lecticans, aggrecan is a constituent of the brain ECM (Yamaguchi, 2000; Bellail et al., 2004) . In particular, aggrecan is thought to be an important component of perineuronal nets (Matthews et al., 2002) , with its expression altered in pathological conditions such as Alzheimer's disease (Morawski et al., 2010) and early-life seizure (McRae et al., 2010) .
Aggrecan is also a major constituent of the ECM of cartilage, and aggrecan degradation is associated with progression of various types of arthritis (Lohmander et al., 1993) . During the development of rheumatoid arthritis (RA), the cartilage matrix is invaded by fibroblasts originating from the synovial lining (Ospelt et al., 2004) . The invading synovial cells have been shown to express a number of ECM-degrading MMPs (Murphy and Nagase, 2008) as well as metalloproteinases with disintegrin and thrombospondin motifs (ADAMTSs) (Yamanishi et al., 2002) . ADAMTS-4 and ADAMTS-5 are thought to be the primary 'aggrecanases' responsible for aggrecan degradation in osteoarthritis (Murphy and Nagase, 2008 ).
Our results demonstrate for the first time that MVs shed by both oligodendroglioma cells and rheumatoid synovial fibroblasts contain a TIMP-3-sensitive aggrecanase activity. This suggests that MVs may contribute to cellular invasion of aggrecan-rich extracellular matrices.
Results

G26/26 MVs cleave aggrecan at several sites
Using a panel of antibodies that recognise aggrecan degradation products, we found that MVs shed by G26/24 oligodendroglioma cells are able to degrade aggrecan at several sites.
Following incubation of 500 nM aggrecan with MVs (4 μg protein) for 24 h at 37°C, aggrecan degradation was visible using the 2-B-6 antibody (Caterson et al., 1985) , which recognises chondroitinasetreated aggrecan fragments (Fig. 1A) . The pattern of the fragments generated by 4 μg of G26/24 MVs mirrored that obtained after incubation of aggrecan with 0.01 nM of recombinant ADAMTS-5.
Aggrecan degradation by G26/24 MVs was further investigated using a panel of neoepitope antibodies that recognise aggrecan cleavage at sites previously shown to be hydrolysed by ADAMTS-4 and ADAMTS-5 (Kashiwagi et al., 2004; Gendron et al., 2007; Troeberg et al., 2008 GRGT sites in the chondroitin sulfate-rich region (Fig. 1A) . The aggrecanase activity of MVs was the same whether 0.05% Brij 35 was included in the assay buffer or not. The degradation products were comparable with those generated by incubation of aggrecan with 0.01 nM recombinant ADAMTS-5 (Fig. 1A) . (Hughes et al., 1995) following incubation of 500 nM aggrecan with 4 μg of MVs for 24 h at 37°C (Fig. 1A) . Incubation of aggrecan with recombinant ADAMTS-5 (5 nM) generated the expected cleavage product. Aggrecan degradation by G26/24 MVs was shown to be time-and dose-dependent. Using the anti-1772 AGEG antibody, degradation of aggrecan by 2 μg of MVs was linear for up to 4 h (Fig. 1B) . Aggrecan degradation was also dose-dependent, with formation of the 1772 AGEG neoepitope increasing linearly over 3 h for 0.1 to 10 μg of MVs (Fig. 1C) .
G26/26 MV aggrecan-degrading activity is inhibited by TIMP-3
We investigated the inhibitor sensitivity of the aggrecandegrading activity of G26/24 MVs by incubating MVs with various proteinase inhibitors and measuring residual activity against the TAQE 1771 -
1772
AGEG site. The metal chelator EDTA (10 mM) blocked the formation of the 1772 AGEG neoepitope, indicating that a metalloproteinase is responsible for degradation (Fig. 2) . GM6001, a hydroxamate metalloproteinase inhibitor, also inhibited aggrecan cleavage by G26/24 MV, with GM6001 inhibiting activity completely at 100 μM and partially at 10 μM (Fig. 2) . TIMP-1 and TIMP-2 (100 nM) had no effect on aggrecan degradation by G26/24 MV, while N-TIMP-inhibited activity strongly and similarly to N-TIMP-3 inhibition of ADAMTS-5. This inhibitory profile indicates that an ADAMTS or related TIMP-3-sensitive metalloproteinase is responsible for the observed aggrecanase activity.
G26/26 cells express aggrecanolytic ADAMTSs
RT-PCR confirmed the expression of Adamts1, Adamts4 and Adamts5 by G26/24 cells (Fig. 3) .
Rheumatoid synovial fibroblast MVs cleave aggrecan in a TIMP-3-sensitive manner
To investigate whether other cell types also shed MVs containing aggrecan-degrading activity, we isolated MVs shed by primary rheumatoid synovial fibroblasts, normal skin fibroblasts and HTB94 chondrosarcoma. The RA synovial fibroblast MVs (4 μg of protein) cleaved aggrecan at the TAQE 1771 -
1772
AGEG bond, while no activity was detected with normal skin fibroblast or HTB94 MVs (4 μg) (Fig. 4A) . Aggrecan degradation by RA fibroblast MVs was inhibited by 100 nM TIMP-3, indicating that this activity is also likely to be due to an ADAMTS or related metalloproteinase.
Discussion
To our knowledge, this is the first description of aggrecanase activity being present in microvesicles shed from two different cell types: oligodendroglioma and rheumatoid synovial fibroblasts. Based on our inhibitor studies, the aggrecanase activity in the shed MVs is likely to be due to ADAMTS metalloproteinase(s). ADAMTS-1, -4, -5, -8, -9, 15, -16 and -18 have all been reported to degrade aggrecan (Murphy and Nagase, 2008) . Among these, ADAMTS-1 (Kuno et al., 2000) , ADAMTS-4 (Kashiwagi et al., 2004) and ADAMTS-5 (Gendron et al., 2007) are the best characterised to date and show the strongest aggrecanase activity. By RT-PCR, we confirmed that G26/24 oligodendroglioma cells express all three of these enzymes, as previously Fig. 2 . Aggrecan degradation by G26/24 MVs is due to a TIMP-3-sensitive metalloproteinase. G26/24 MVs (4 μg) or ADAMTS-5 (0.001 nM) were incubated alone (−) or with EDTA (10 mM), TIMP-1 (100 nM), TIMP-2 (100 nM), GM6001 (5-100 μM) or N-TIMP-3 (5-100 nM) (1 h, 37°C). Residual activity against aggrecan (3 h, 37°C) was visualised using the anti-1772 AGEG neo-epitope antibody.
Fig. 3. G26/24 cells express ADAMTS-1, ADAMTS-4 and ADAMTS-5. RT-PCR for
Adamts1, Adamt4 and Adamts5 was performed on total RNA isolated from G26/24 cells and MEF cells. Negative controls were performed without template. shown for glioblastomas (Held-Feindt et al., 2006) . RA synovial fibroblasts are known to express ADAMTS-4 and ADAMTS-5 (Yamanishi et al., 2002 GRGT site . Our data may thus indicate that the aggrecan-degrading activity in G26/24 MVs has similar properties and is associated with a heparan sulfate proteoglycan on the surface of MVs. Membrane-associated aggrecanase activity was first described by Billington et al. in preparations of bovine nasal chondrocyte membranes (Billington et al., 1998) . ADAMTS-4 is thought to associate with syndecan 1 on the surface of chondrosarcoma cells (Gao et al., 2004) , and ADAMTS-5 to associate with syndecan 4 on chondrocytes (Echtermeyer et al., 2009) . We thus postulate that the aggrecanase activity is associated with the surface of the MVs through interaction with heparan sulfate proteoglycans.
Both oligodendroglioma and rheumatoid synovial fibroblasts are capable of invading into brain and cartilage extracellular matrices, which are rich in lectican chondroitin sulfate proteoglycans such as aggrecan, versican, brevican and neurocan. Our findings suggest that shed MVs may contribute to the ECM-degrading and invasive capacity of the cells. Degradation of brevican by ADAMTSs has been shown to generate a cleaved fragment that increases the invasiveness of glioma cells (Nakada et al., 2005) , suggesting that aggrecanase activity in shed MVs may also indirectly increase invasive capacity. The presence of ADAMTSs in shed MVs may represent a novel mechanism by which cells target these enzymes to lectican substrates in diverse extracellular matrices.
Experimental procedures
Materials
Human ADAMTS-5 lacking the C-terminal thrombospondin domain (Gendron et al., 2007) , bovine aggrecan (Hascall and Sajdera, 1969) , TIMP-1 (Troeberg et al., 2002) , TIMP-2 (Troeberg et al., 2002) , TIMP-3 (Troeberg et al., 2009 ) and N-TIMP-3 (Kashiwagi et al., 2001 ) were prepared as previously described. GM6001 was from Elastin Products (Owensville, USA).
Cell culture
Murine G26/24 oligodendroglioma and human HTB94 chondrosarcoma cells were maintained in DMEM supplemented with 10% foetal calf serum, and 1% penicillin/streptomycin. Human synovial fibroblasts were obtained with ethics approval and informed consent from synovial tissue of RA patients undergoing joint replacement surgery as previously described (Miller et al., 2009) . Normal human skin fibroblasts were obtained with ethics approval and informed consent from patients undergoing surgery for Dupuytren's disease as previously described (Verjee et al., 2009 ).
Preparation of MVs from conditioned medium
MVs were prepared from media conditioned for 24 h on subconfluent cells. Media were centrifuged at 2000 g (15 min, 4°C) and 4000 g (15 min, 4°C) to remove debris. MVs were collected from the supernatant by centrifugation at 105 000 g (90 min, 4°C) and re-suspended in phosphate-buffered saline, pH 7.5. MVs were quantified based on protein content using the Bradford assay (Protein Assay Reagent, Bio-Rad, UK) with BSA as a standard protein.
Aggrecanase assay
Aggrecan (500 nM, 50 μg in 50 μl assay volume) was incubated with MVs or ADAMTS-5 in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM CaCl 2 , and 0.05% Brij 35 at 37°C. For inhibitor analysis, ADAMTSs or MVs were pre-incubated with inhibitors (1 h, 37°C) before addition of aggrecan. Samples were prepared for immunoblotting by treatment with chondroitinase ABC and keratanase (Seikagaku, Japan) (0.01 units each, 16 h, 37°C) and precipitation with acetone (5 volumes, − 20°C, 18 h). Degradation was visualised using antibodies recognising degraded aggrecan fragments as before . The 2-B-6 antibody recognises chondroitinase-treated aggrecan (Caterson et al., 1985) ; anti-374 ARGSV recognises aggrecan cleaved at NITEGE 373 -374 ARGSV (Hughes et al., 1995) , anti-GELE 1480 recognises aggrecan cleaved at . Blots were quantified using ImageJ software.
RT-PCR
Adamts expression was evaluated by RT-PCR of the total RNA extracted from G26/24 and mouse embryonic fibroblasts (MEF) using a QIAamp RNA Blood Mini Kit (Qiagen Ltd, UK). Primers for Adamts1 amplification were: 5′-CAGGAAGCATAAGGAAGAAG-3′ (forward) and 5′-GCACAGTGCTTAGCATCATCA-3′ (reverse), for Adamts4: 5′-ATGTGGG-CACAGTGTGTGAT-3′ (forward) and 5′-CAAGGTGAGTGCTTCGTCTG-3′ (reverse), and for Adamts5: 5′-GGCATCATTCATGTGACACC-3′ (forward) and 5′-CGAGTACTCAGGCCCAAATG-3′ (reverse) (Stanton et al., 2005) .
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